Research Paper Volume 13, Issue 10 pp 14342—14354

LncRNA MEG8 promotes TNF-α expression by sponging miR-454-3p in bone-invasive pituitary adenomas

Hai-Bo Zhu2, *, , Bin Li1, *, , Jing Guo1, , Ya-Zhou Miao1, , Yu-Tao Shen1, , Ya-Zhuo Zhang1,2,3,4, , Peng Zhao2, &, , Chu-Zhong Li1,2,3,4, ,

  • 1 Beijing Neurosurgical Institute, Capital Medical University, Fengtai 100070, Beijing, China
  • 2 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Fengtai 100070, Beijing, China
  • 3 Beijing Institute for Brain Disorders Brain Tumor Center, Fengtai 100070, Beijing, China
  • 4 China National Clinical Research Center for Neurological Diseases, Fengtai 100070, Beijing, China
* Equal contribution

Received: May 23, 2020       Accepted: February 16, 2021       Published: May 19, 2021
How to Cite

Copyright: © 2021 Zhu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


There are few studies on the mechanism of pituitary adenoma (PA) destroying bone. The current study aimed to investigate the role of MEG8/miR-454-3p/TNF-α in bone-invasive pituitary adenomas (BIPAs). In this study, we report that lncRNA MEG8 and TNF-α are upregulated in BIPA tissues while miR-454-3p is downregulated, which is associated with poor progression-free survival (PFS). Functional assays revealed the role of up-regulated MEG8 and down-regulated miR-454-3p in promoting bone destruction. Mechanistically, MEG8 promotes TNF-α expression by sponging miR-454-3p, which ultimately leads to the occurrence of bone destruction. The mechanism is confirmed in vivo and in vitro. Therefore, our data illustrated a new regulatory mechanism of MEG8/miR-454-3p/TNF-α in BIPAs. It may provide a useful strategy for diagnosis and treatment for BIPA patients.


PA: pituitary adenoma; BIPA: bone-invasive pituitary adenoma; NIPA: noninvasive pituitary adenoma; PFS: progression-free survival; TNF-α: Tumor necrosis factor-alpha; ceRNAs: competing endogenous RNAs; lncRNAs: long noncoding RNAs; miRNA: microRNA.